Key takeaways
Incruse Ellipta (umeclidinium) and Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) are both inhalers used for the maintenance treatment of chronic obstructive pulmonary disease (COPD), but they have some key differences. Incruse Ellipta contains only one medication, umeclidinium, which is a long-acting muscarinic antagonist (LAMA) that helps relax the muscles in your airways. Trelegy Ellipta, on the other hand, is a combination inhaler that includes three medications: fluticasone (an inhaled corticosteroid), umeclidinium (a LAMA), and vilanterol (a long-acting beta-2 agonist). This combination works together to reduce inflammation, relax airway muscles, and open up the airways. Trelegy Ellipta is also approved for asthma, while Incruse Ellipta is not. Additionally, you need to rinse your mouth after using Trelegy Ellipta to prevent fungal infections, a step that is not required with Incruse Ellipta. Both inhalers are used once daily, but Trelegy Ellipta offers a more comprehensive treatment by combining three medications in one.
